## Marisa Liliana Fernandez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8037784/publications.pdf

Version: 2024-02-01

18 252 8 papers citations h-index

20 20 20 328 all docs docs citations times ranked citing authors

15

g-index

#	Article	IF	CITATIONS
1	New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 833-837.	3.2	67
2	Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole. Memorias Do Instituto Oswaldo Cruz, 2016, 111, 218-221.	1.6	36
3	Trypanosoma cruzi loop-mediated isothermal amplification (Trypanosoma cruzi Loopamp) kit for detection of congenital, acute and Chagas disease reactivation. PLoS Neglected Tropical Diseases, 2020, 14, e0008402.	3.0	24
4	Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma cruzi-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes. Frontiers in Immunology, 2018, 9, 1958.	4.8	22
5	New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
6	Clinical and epidemiological features of chronic Trypanosoma cruzi infection in patients with HIV/AIDS in Buenos Aires, Argentina. International Journal of Infectious Diseases, 2018, 67, 118-121.	3.3	14
7	Clinical profile and mortality in patients with T. cruzi/HIV co-infection from the multicenter data base of the "Network for healthcare and study of Trypanosoma cruzi/HIV co-infection and other immunosuppression conditions― PLoS Neglected Tropical Diseases, 2021, 15, e0009809.	3.0	12
8	Evaluation of the immune response againstTrypanosoma cruzicytosolic tryparedoxin peroxidase in human natural infection. Immunology, 2018, 155, 367-378.	4.4	11
9	In Silico Guided Discovery of Novel Class I and II <i>Trypanosoma cruzi</i> Epitopes Recognized by T Cells from Chagas' Disease Patients. Journal of Immunology, 2020, 204, 1571-1581.	0.8	10
10	Loop-Mediated Isothermal Amplification of Trypanosoma cruzi DNA for Point-of-Care Follow-Up of Anti-Parasitic Treatment of Chagas Disease. Microorganisms, 2022, 10, 909.	3.6	9
11	The cytosolic tryparedoxin peroxidase from <i>Trypanosoma cruzi</i> induces a proâ€inflammatory Th1 immune response in a peroxidatic cysteineâ€dependent manner. Immunology, 2021, 163, 46-59.	4.4	6
12	Benznidazole in Cerebrospinal Fluid: a Case Series of Chagas Disease Meningoencephalitis in HIV-Positive Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	5
13	Trypanosoma cruzi Induces Regulatory B Cell Alterations in Patients With Chronic Chagas Disease. Frontiers in Cellular and Infection Microbiology, 2021, 11, 723549.	3.9	5
14	Chagas cardiomyopathy associated with serological cure after trypanocidal treatment during childhood. Revista Da Sociedade Brasileira De Medicina Tropical, 2018, 51, 557-559.	0.9	4
15	Ex vivo characterization of Breg cells in patients with chronic Chagas disease. Scientific Reports, 2021, 11, 5511.	3.3	4
16	lgE antibodies against Trypanosoma cruzi arginine kinase in patients with chronic Chagas disease. Molecular Immunology, 2021, 138, 68-75.	2.2	1
17	COVID-19 and Chagas Disease in Buenos Aires, Argentina. Frontiers in Tropical Diseases, 2022, 2, .	1.4	1
18	Experiencias del personal de salud sobre la implementaci $\tilde{A}^3$ n de pr $\tilde{A}_1$ cticas de protecci $\tilde{A}^3$ n contra COVID-19 en Argentina. Ortado $\tilde{A}$ ve G $\tilde{A}$ = Journal of Middle East and Migration Studies, 0, , .	0.0	0